Societas Cancer Americana aestimat plus 97,000 homines in Civitatibus Foederatis cum cancro colorectali hoc anno dignosci et mortes circiter 50,600 esse facturum. Tertia est communissima cancer in Civitatibus Foederatis Americae, et secunda causa mortis cancri ducens.
Quamvis cancer colorectalis protegendo monstratum sit efficax in reducendis mortibus cancer, investigatores referunt numerum screeners nimis parvum esse. Hodierna ACS normas exercitationi commendant protegentes pro coetibus periculosis 45 annos et maiores natu, utentes examen fecalum sensitivum seu structurale (visual) examen et omnes eventus positivi colonoscopii esse debent. Quamvis his commendationibus, studium differentias significantes in rates protegendis invenit, in iis ethnicitatis, geographicae, aliorumque factorum oeconomicorum.
Quoniam colorectal cancer is a preventable disease, efforts are being made throughout the country to increase the screening rate of colorectal cancer, but the screening rate is only about 63%, while the screening rate of low-income and other vulnerable groups is often lower.
The latest research suggests that with stool immunochemical tests, or FIT kits, they can detect blood in stool and common symptoms of colon cancer. The patient can complete the test at home and return it to the provider for analysis. Patients with a positive result of the FIT kit test will be scheduled for colonoscopy.
In studio, XXI% de aegris qui accepit MORBUS COMITIALIS ornamentum perficitur in protegendo test, et qui perficitur a MORBUS COMITIALIS XVIII alius test eventus habuit, et eorum, requiritur XV colonoscopy. X De aegris qui perficitur a colonoscopy, patientes estote I had praecessi alius.
Num haec abiens de Inquisitores a cogitationibus suis donec permanere studiis modum potest implemented in dies maiora certamina serebat, et discere magis de quam ad sumptus-efficaciam et absconsionem augendam rate of vulnerable coetus.
